This study was designed to determine if Brucella abortus strain RB51, which expresses small amounts of the lipopolysaccharide O side chain, would cause positive responses on brucellosis serologic surveillance tests when given to adult cattle that were vaccinated as calves with B. abortus strain 19. Cattle vaccinated as adults with strain RB51 that had been vaccinated as calves with strain 19 (n = 40) had significantly greater antibody titers (P < 0.05) against strain RB51 at 4 and 8 weeks postvaccination in the dot blot assay than did animals (n = 10) not vaccinated with strain RB51. When evaluated using the card or buffered acid plate agglutination presumptive tests, 7 strain RB51 vaccinates tested positive at either 4 or 8 weeks following vaccination as compared with 4 cattle in the control group that were not vaccinated with strain RB51. One strain RB51 vaccinate was scored as suspect on the standard tube agglutination (STA) test at 8 weeks following vaccination. Remaining samples from strain RB51 vaccinates tested negative on the STA, complement fixation (CF), rivanol, and particle concentration fluorescence immunoassay (PCFIA) confirmatory tests. Samples from 2 control cattle were PCFIA positive at time 0; 1 of these animals was CF positive throughout the study. This study suggests that use of strain RB51 in cattle vaccinated with strain 19 as calves will not responses on confirmatory tests and will not impair brucellosis serologic surveillance efforts.
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cause positive
For over 50 years 6 the Brucella abortus strain 19 (S19) vaccine has been used in cattle to prevent abortion and infertility caused by natural infection with virulent B. abortus strains. The S19 vaccine, combined with serologic surveillance tests, has been instrumental in the success of the brucellosis eradication program. Conventional serologic tests for brucellosis detect antibody against the lipopolysaccharide (LPS) O antigens induced by vaccination with S19 or exposure to virulent field strains. Therefore, routine serologic tests cannot differentiate S19-vaccinated cattle from cattle infected with virulent B. abortus field strains. As the commonly used because of their relatively high sensitivity to screen multiple serum samples. 4, 7 When samples test positive on screening tests, presumptive tests with relatively high specificity, such as rivanol, standard tube agglutination (STA), or complement fixation (CF), are used to confirm that serologic responses are due to brucellosis infection. The particle concentration fluorescence immunoassay (PCFIA) has been used as both a presumptive or confirmatory test in different states. In this report, the PCFIA is considered a confirmatory test.
Recently, a rough mutant of the virulent 2308 strain numbers of Brucella-infected herds are reduced, the of B. abortus, strain RB51 (SRB51), has been proposed problem of retained antibody titers to the LPS O antifor use as a vaccine for cattle of all ages. Although gen following S19 vaccination becomes more signifi-SRB51 expresses low levels of the O side chain, 8 naive cant and may impair the progression of the eradication animals remain seronegative on surveillance tests folprogram.
lowing vaccination with SRB51. 10 Potential use of Brucellosis serologic tests are often subdivided into SRB51 could include vaccination of adult cattle in presumptive or confirmatory tests. Tests such as the infected or exposed herds that may have been vaccicard or buffered acid plate agglutination (BAPA) are nated as calves with S19. If SRB51 is used in this manner, identification of brucellosis-infected cattle would be impaired if SRB51 induces an anamnestic From the USDA, Agricultural Research Service, National Animal humoral response against the LPS O side chain in an-
Materials and methods
A master seed stock of B. abortus strain RB51 (ARS-1) a was obtained and passed 8 times on tryptose agar b containing 5% bovine serum before growth for 48 hr at 37 C for lyophilization. The bacteria were harvested as previously described 1 and suspended in WHO medium. A 500-µl aliquot containing 5 x 10 10 SRB51 was placed into vials, lyophilized, c and stored at -70 C. Prior to use, the lyophilized SRB51 were suspended in saline (0.15 M Nacl, pH 6.4).
Adult cows (2-10 yr of age) from 2 herds were vaccinated on separate occasions with 2 ml of SRB51 vaccine (8.4 x 10 8 -1.3 x 10 9 colony-forming units [CFU]). The vaccine was subcutaneously injected in the cervical region. From these 2 herds, 40 cattle that had received the S19 vaccine as calves were randomly selected for the SRB51 vaccine group. Prior to SRBS1 vaccination, 10 calfhood-vaccinated cattle were randomly selected for the control group and did not receive the SRB51 vaccine.
Blood was obtained before vaccination and at 4 and 8 weeks after vaccination. Blood was allowed to clot for 12 hr at 4 C before centrifugation. Serum was measured for antibodies against B. abortus using the card, b BAPA, CF, STA, and PCFIA d tests as described. 1, 9 Antibodies against B. abortus SRB51 were measured by a previously described dot-blot assay. 3 Results of the card and BAPA tests were positive when samples produced a visible agglutination. The CF test results giving a 2 + reaction at a 1:10 or higher dilution were scored as positive. Samples analyzed in the PCFIA were scored as positive if the sample fluorescence/negative fluorescence ratio was less than 0.301, as suspect if the ratio was between 0.301 and 0.600, and as negative if the ratio was Titers in the SRB51 dot-blot assay were analyzed by a general linear analysis procedure. Means for SRB51-vaccinated and nonvaccinated groups were compared by a least significant difference procedure. Data are presented as mean ± SEM, with significant differences reported at P ≤ 0.05.
Results
The SRB51 dot-blot assay detected antibody titers in the SRB51-vaccinated cattle at 4 and 8 weeks that were greater than titers of cattle that were not vaccinated with SRB51 (P < 0.05) ( Fig. 1) . Dot-blot titers of SRB51-vaccinated cattle were lower at 8 weeks than at 4 weeks (P < 0.05).
Samples from 6RB51 vaccinates were not evaluated using the BAPA test at 0 or 8 weeks. Prior to vaccination, sera from all cattle vaccinated with SRB51 were negative in card and BAPA tests. (Table 1 ). In comparison, 4 control animals that were not vaccinated with SRB51 tested positive on these presumptive tests at various times throughout the study. Presumptive tests were positive in 7 SRB51-vaccinated cattle: 3 One card-positive, BAPA-positive sample from an SRB51 vaccinate was scored as suspect on the STA test at 8 weeks following vaccination. With the exception of this sample, SRB51-vaccinated cattle were neg-ative on the STA, CF, PCFIA, and rivanol tests at all times. In comparison to SRB51 vaccinates, 1 control animal was scored as suspect on the PCFIA test at time 0 and positive on the CF test throughout the course of the experiment. A sample from a second control animal also tested suspect on the PCFIA test at time 0. With the exception of these 2 animals, responses of control animals were negative on confirmatory tests.
Discussion
Data from this study suggest that use of the SRB51 vaccine in adult cattle will not interfere with identification of infected animals even if administered to cattle vaccinated with S19 as calves. Although some SRB51vaccinated animals were seropositive on the presumptive tests after vaccination (5-21%), responses were similar in the control group (10-30%). Positive responses on presumptive tests by cattle in our study may reflect their status as S19 vaccinates or the reported relatively high sensitivity but low specificity of these tests. 4, 7 We did not find positive antibody titers in samples evaluated by confirmatory brucellosis serologic tests, which are considered higher in specificity that the presumptive tests. Previous work in Brucellainfected cattle has indicated that although sensitivity of the card test is high (99.6%), its specificity is low (9.6%) when compared with tests such as the PCFIA, CF, or rivanol (48.6%, 56.0%, and 61.8%, respectively). 7 The 95.4% sensitivity of the BAPA test when used in brucellosis-free or brucellosis-infected herds would make it an acceptable screening test, whereas the 100% specificity of the CF test would suggest its use as a confirmatory test. 4 A lower specificity has been reported for the STA than for the CF test (84.2% vs. 100%), 4 although in that study samples evaluated with the STA were considered positive when agglutination was present at a 1/50 dilution as compared with the 1/200 dilution threshold used in our study. The lack of positive responses by SRB51 vaccinates on the STA, PCFIA, CF, and rivanol confirmatory tests throughout this study suggests that use of SRB51 in cattle vaccinated with S19 as calves will not impair brucellosis serologic surveillance efforts.
The lack of a anamnestic humoral response to the O side chain following SRB51 vaccination in cattle vaccinated with S19 as calves most likely reflects a very low expression of the LPS O side chain by SRB51. Studies have indicated that LPS from SRB51 reacts weakly with a monoclonal antibody specific for the perosamine O side chain of B. abortus and that cattle hyperimmunized with SRB51 in Freund's complete adjuvant do not produce antibodies against the LPS O side chain. 8 Results of this study are similar to those from another study in which naive cattle given 1 x 10 10 CFU SRB51 remained negative when evaluated by conventional serologic tests for brucellosis. 10 A higher SRB51 dosage might cause seroconversion in adult cattle that have been vaccinated with S19 as calves. However, our data suggest that this is unlikely because cattle evaluated in this study had antibodies to SRB51 as indicated by the significant increases in titers on the dot-blot assay, whereas none tested seropositive on the CF, STA, rivanol, or PCFIA tests.
Previous studies have indicated that cattle vaccinated with 1 x 10 10 CFU of SRB51 between the ages of 3 and 10 months demonstrate significant protection against challenge with virulent B. abortus strain 2308 (S2308) when compared with nonvaccinated cattle. 2, 3 Cattle infected with field isolates can also be readily identified using routine serologic surveillance tests; SRB51 vaccinates seroconvert following intraconjunctival challenge with S2308 (unpublished data). Because S19 can cause persistent titers that confound identification of infected cattle, the SRB51 vaccine offers diagnostic advantages. Use of SRB51 as a vaccine will increase the efficiency of identifying Brucella-infected cattle while maintaining the benefits of vaccine-induced protective immunologic responses.
